Latest News and Press Releases

Helsinn to co-host alongside Recordati Rare Diseases satellite symposium on MF-CTCL diagnosis optimization at European Academy of Dermatology and Venereology Congress 2019 Lugano, Switzerland,...

Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical...

Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical group focused on...

Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological...

Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology       The Award recognizes Patient Entrepreneurs demonstrating...

Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14th Monaco Biennale of Oncology 2020       The Award recognizes Patient...

Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada DUBLIN and LUGANO, July 31, 2019 -- Endo International plc (NASDAQ: ENDP),  and Helsinn, a Swiss...

Helsinn Investment Fund Announces First Exit Luxembourg, July 15, 2019 – Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient...

Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors Lugano, Switzerland, June 26, 2019: Helsinn, the Swiss pharmaceutical group focused on...

Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress Symposium will explore the...